查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1835273

醫院感染治療市場（按藥物類別、給藥途徑、最終用戶、分銷管道和應用）—2025-2032 年全球預測

Hospital Infection Therapeutics Market by Drug Class, Route Of Administration, End User, Distribution Channel, Application - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，醫院感染治療市場規模將達到 122.8 億美元，複合年成長率為 8.52%。

主要市場統計數據
基準年2024年 63.8億美元
預計2025年 69.2億美元
預測年份：2032年 122.8億美元
複合年成長率（%） 8.52%

簡要介紹醫院感染治療的臨床、商業和營運背景，強調採取綜合策略應對措施的必要性

醫院獲得性抗菌藥物仍然是病患安全和醫療品質的核心支柱，它與臨床實踐、供應鏈韌性和監管監督息息相關。近年來，採購、抗菌藥物管理和分銷管道方面存在的漏洞暴露無遺，亟需採取更全面的觀點，將臨床重點與商業性現實結合。本執行摘要概述了醫院領導、製造商和經銷商在製定策略和營運應對措施時必須考慮的關鍵主題。

這種模式的特點是各種因素的融合，包括病原體譜和抗藥性模式的演變、新型抗病毒藥物和抗真菌藥物的成熟、消毒通訊協定的持續重要性，以及採購團隊為確保關鍵療法的持續可及性而承受的日益增加的壓力。因此，相關人員必須在緊急營運需求與在產品線開發、管理計畫和替代籌資策略的中長期投資之間取得平衡。本引言為系統性地探討轉型轉變、關稅相關阻力、細分資訊、區域差異、競爭動態、建議行動以及本報告所依據的研究嚴謹性奠定了基礎。

分析重新定義醫院感染藥物和相關人員合作的臨床、製造和分銷轉型

醫院感染治療領域正經歷變革時期期，其驅動力來自幾個趨勢，這些趨勢正在重塑臨床決策和供應鏈結構。快速診斷和就地檢驗的進步使得治療方法選擇更具針對性，並逐漸將重點從廣泛的經驗性方案轉向精準標靶治療。同時，管理計畫與採購獎勵的連結日益緊密，形成了一個反饋循環，處方決策將同時考慮臨床療效和抗藥性緩解的必要性。

分銷模式與臨床創新同步發展。採購日益數位化、線上藥局履約的擴張以及批發商利潤的壓力，迫使醫院和醫療系統重新評估直接採購、代銷模式和策略庫存緩衝。腸外給藥和無菌注射劑向專業化生產的轉變，加上對品質和法規合規性的嚴格審查，意味著供應的連續性取決於強大的供應商合格和關鍵投入的地理分佈。總而言之，這些轉變要求臨床領導者與供應鏈和商業團隊更緊密地合作，以使治療策略與採購可靠性和成本控制相一致。

全面分析新的關稅動態如何加劇供應鏈脆弱性、採購複雜性以及醫院治療的臨床替代策略

即使關稅政策的改變不會直接影響成品藥品，也會對醫院感染治療產品整體產生巨大影響。對原料藥、無菌製劑、一次性設備和包裝徵收更高的關稅，可能會增加到岸成本，並擠壓製造商和經銷商的淨利率。因此，採購團隊在成本預測和合約談判方面面臨更大的複雜性，製造商正在重新評估其供應商佈局，並考慮將關鍵生產環節回流或近岸外包。

關稅環境也加劇了現有腸外和無菌產品供應鏈的脆弱性，專用設備和檢驗的生產基地限制了產能的快速擴張。依賴即時庫存模式的醫院將更容易受到間歇性供不應求的影響，迫使其進行策略性調整，例如安全庫存、多方採購以及更長的合約期限，其中包含處理不可抗力和成本轉嫁的條款結構。同時，進口成本的上升將鼓勵對本地製造業的投資，但由於此類轉型需要資金、監管調整和時間，因此短期影響將主要透過合約策略和庫存政策來管理。

臨床上，與關稅相關的變化可能會改變某些藥物類別的供應和採購優先順序。機構可能會優先考慮治療等效的學名藥或替代抗菌劑型，以維持醫療服務的連續性。因此，抗菌藥物管理團隊必須與採購和處方委員會合作，更新治療途徑，並確保替代藥物在滿足管理目標的同時保持臨床有效性。整體而言，關稅變化是一種強制機制，有助於促進臨床、供應鏈、監管和財務職能之間的協調。

按藥物類別、給藥途徑、最終用戶、分銷管道和應用分類的關鍵細分洞察

要了解市場，需要詳細了解藥品類別、給藥途徑、最終用戶、分銷管道和應用。藥物類別包括抗生素、抗真菌藥物、消毒劑和抗病毒藥物；抗生素包括卡巴培南類、頭孢菌素類、Fluoroquinolones和青黴素類等亞類；抗真菌藥物包括Azole、棘白菌素類和Polyenes；消毒劑包括酒精製劑、洛赫西定和碘；每個類別都有不同的臨床使用模式、管理考慮、製造要求和監管途徑，這些因素共同影響採購重點和醫院處方箋。

給藥途徑——吸入、口服、腸外和局部——決定了臨床路徑和物流，使其成為決定臨床部署和供應複雜性的關鍵因素。腸外給藥特別分為肌肉注射、靜脈注射和皮下注射，給藥需要專門的無菌生產、低溫運輸考量和護理技能。最終用戶，包括門診手術中心、診所、居家醫療機構和醫院，具有不同的購買力、儲存基礎設施和治療通訊協定，需要量身定做的分銷方式和患者教育策略。分銷管道也各不相同，包括醫院藥房、線上藥房、零售藥房和批發商，每個管道都有不同的前置作業時間、合約規範和合規義務。

治療方法選擇和庫存規劃由應用細分驅動：安寧療護、預防治療和治療。而治療又分為經驗性療法和標靶治療，每種療法都需要不同的診斷和管理支持。整合這些細分層面，使相關人員能夠更好地協調臨床路徑與供應鏈設計，將合適的配方、途徑和分銷管道與合適的最終用戶和應用相匹配。

關鍵區域洞察和地理動態將如何影響臨床應用、製造和分銷策略

美洲、歐洲、中東和非洲以及亞太地區的區域動態對治療藥物的可近性、監管預期和商業策略有重大影響。在美洲，醫院系統的整合和對基於價值的採購的重視推動了對具有明顯臨床和經濟效益的治療藥物的需求，分銷網路通常以集中式集團採購和整合供應協議為導向。相較之下，歐洲、中東和非洲的法規環境和採購框架各不相同，國家法規、報銷機制和區域製造地決定藥物的可及性和定價。強調抗生素管理和感染預防的政策舉措也因司法管轄區而異。

亞太地區呈現出多元化的動態，一些市場醫療產能快速擴張，而其他市場則擁有先進的製造能力。該地區一些國家優先發展本地生產和出口導向製藥產業，影響原料藥和無菌成分的全球供應鏈。這些地理差異要求製造商和經銷商採取差異化的市場開發方法，投資監管情報，並制定針對特定區域的供應鏈冗餘。總體而言，區域策略必須考慮監管時間表、採購實踐、製造集中度以及臨床實踐的差異，以確保藥品的可用性和適當的臨床使用。

公司對競爭定位、創新重點和供應鏈作用的關鍵見解

競爭格局多種多樣，涵蓋跨國製藥創新企業、專注於新型抗生素和抗病毒藥物的專業生物技術公司、學名藥製造商以及促進醫院可及性的經銷商。擁有廣泛感染疾病產品組合的行業領導者通常將抗病毒和抗生素研發與大規模生產和成熟的分銷網路相結合，從而能夠快速部署經臨床檢驗的新型療法。專業生物技術公司和學術衍生公司通常是下一代藥物和輔助性治療的來源，而學名藥和契約製造製造商在維持成本效益和生產彈性方面發揮關鍵作用。

分銷和藥房服務供應商正日益透過附加價值服務（例如臨床支援工具、管理分析和庫存管理解決方案）來凸顯自身差異化。這一趨勢凸顯了製造商與經銷商夥伴關係的重要性，以確保及時的供應和臨床醫生教育能夠支持管理目標和處方決策。此外，投資於無菌生產能力和品質系統的公司在醫院腸外用藥市場中佔據有利地位，該市場由於監管審查和對生產檢驗的要求而面臨較高的進入門檻。深入了解此類企業策略可以幫助相關人員評估合作夥伴的選擇、潛在的收購和合作機會，從而增強供應的連續性和臨床療效。

為行業領導者提供切實可行的建議，以增強韌性、管理和商業性績效

產業領導者應優先考慮跨職能管治，將臨床、採購、監管和商業團隊整合在一起，共同製定配方決策、合約結構和應急計畫。加強供應商資格認證流程，並實現原料藥和無菌成分供應商的多元化，可以減少地理和政策干擾帶來的風險。同時，投資診斷驗證和管理分析，可以將藥物利用轉向標靶治療，保持臨床有效性，並減緩抗藥性趨勢。

商業和分銷策略必須適應不斷變化的採購行為，提供靈活的合約模式、經過認證的供應保證以及臨床應用的教育支援。擁有無菌生產能力和強大品質系統的製造商應考慮產能訊號和策略夥伴關係，以滿足醫院的需求。此外，將情境規劃納入策略評估，可以幫助組織應對關稅變化、監管變化和突發需求激增，明確定義庫存調整、替代採購或治療方案替換的觸發點。結合這些步驟可以增強應對能力，同時使商業性獎勵與臨床品質目標保持一致。

調查方法和資料來源、分析框架以及研究結果背後的檢驗方法的描述

調查方法結合了臨床領導者、採購專業人員和行業高管的初步意見，以及對監管備案文件、品質指南和開放原始碼行業報告的二次分析。定性訪談揭示了營運限制和應用障礙的相關背景，而供應鏈圖譜則確定了原料藥採購、無菌成分和分銷流程中的關鍵節點。此分析框架將臨床路徑圖譜與供應商風險評估和商業管道評估相結合，以產生全面的洞察。

檢驗結合了訪談回饋、製造商資訊揭露以及公開的監管行動摘要。採用情境分析來評估在供應中斷和政策變化下的韌性，尤其關注腸外製劑的生產限制和分銷管道摘要。強調假設的透明度和方法步驟的可重複性，以便相關人員能夠根據其內部決策調整方法，並根據需要進行有針對性的盡職實質審查。

結論：臨床結果、供應連續性和協作實施的策略重點總結

醫院感染治療兼具臨床緊迫性與運作複雜性。確保患者安全和有效獲得治療，需要臨床管理、採購政策、生產策略和分銷設計等方面的全面行動。近期貿易政策變化、臨床診斷技術的不斷發展以及分銷模式的轉變，都增加了跨職能協調和應急計劃的需求。積極實現供應多元化、投資診斷主導製劑並建立靈活商業協議的組織將能夠保持連續性並支持最佳臨床療效。

最終，成功取決於將洞見轉化為實踐，例如根據管理目標制定方案，確保關鍵無菌產品的多種供應來源，以及利用能夠提供臨床推廣和庫存解決方案的夥伴關係。採取策略性和全面性的方法將有助於醫院、製造商和經銷商緩解短期中斷，並建立應對未來感染護理挑戰所需的適應能力。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

  • 醫院抗菌藥物管理計畫的成長，最佳化了抗生素的使用，減少了抗藥性的出現
  • 引進快速分子診斷技術，可在患者入院後數小時內進行針對性感染治療
  • 加強人工智慧驅動的預測分析的整合，以便及早發現醫院內感染
  • 針對加護病房中耐多藥銅綠假單胞菌的噬菌體混合物的開發
  • 預防困難梭狀桿菌感染疾病復發的輔助單株抗體輔助性治療的出現
  • 在醫療設備中引入抗菌表面塗層，以防止導管中生物膜的形成
  • 擴大以遠端醫療為基礎的感染疾病諮詢服務，以管理住院患者的抗菌通訊協定
  • 管理方案要求即時追蹤和報告整個醫院網路的抗生素使用情況
  • CRISPR-Cas 抗菌藥物取得進展，旨在選擇性消除醫院中的抗藥性菌株
  • 利用次世代定序即時監測抗性基因通路

第6章：2025年美國關稅的累積影響

第7章：人工智慧的累積影響，2025年

8. 醫院感染治療市場（依藥物類別）

  • 抗生素
    • 卡巴培南類
    • 頭孢菌素類
    • Fluoroquinolones
    • 大環內酯類
    • 青黴素
  • 抗真菌藥物
    • Azole
    • Echinocandins
    • Polyenes
  • 消毒劑
    • 酒精類
    • 洛赫西定
    • 帶碘化合物
  • 抗病毒藥物
    • 抗B肝病毒
    • 抗HCV
    • 抗愛滋病毒
    • 抗流感

9. 醫院感染治療藥物市場（依給藥途徑）

  • 吸入
  • 口服
  • 腸外
    • 肌肉注射
    • 靜脈
    • 皮下
  • 外用

第 10 章醫院感染治療藥物市場（依最終使用者）

  • 門診手術中心
  • 診所
  • 家庭環境
  • 醫院

第11章 醫院感染治療藥物市場（依通路）

  • 醫院藥房
  • 網路藥局
  • 零售藥局
  • 批發商

第12章醫院感染治療藥物市場（依應用）

  • 安寧療護
  • 預防
    • 術後
    • 術前
  • 治療
    • 經驗
    • 標靶治療

第13章醫院感染治療藥物市場（按地區）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章醫院感染治療藥物市場（依類別）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章醫院感染治療藥物市場（按國家）

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章競爭格局

  • 2024年市佔率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • Pfizer Inc.
    • Merck & Co., Inc.
    • GlaxoSmithKline plc
    • Sanofi SA
    • F. Hoffmann-La Roche Ltd
    • Novartis AG
    • Bayer AG
    • AbbVie Inc.
    • Astellas Pharma Inc.
    • DAIICHI SANKYO COMPANY
Product Code: MRR-43127F7278A5

The Hospital Infection Therapeutics Market is projected to grow by USD 12.28 billion at a CAGR of 8.52% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 6.38 billion
Estimated Year [2025] USD 6.92 billion
Forecast Year [2032] USD 12.28 billion
CAGR (%) 8.52%

Concise introduction framing the clinical, commercial, and operational context for hospital infection therapeutics while highlighting the need for integrated strategic responses

Hospital infection therapeutics remain a central pillar of patient safety and quality of care, intersecting clinical practice, supply chain resilience, and regulatory oversight. Recent years have exposed vulnerabilities across procurement, antimicrobial stewardship, and distribution channels, requiring a more integrated perspective that aligns clinical priorities with commercial realities. This executive summary synthesizes critical themes that hospital leaders, manufacturers, and distributors must consider when shaping strategy and operational responses.

The landscape is characterized by a convergence of factors: evolving pathogen profiles and resistance patterns; the maturation of novel antiviral and antifungal agents; the sustained importance of antiseptic protocols; and mounting pressure on procurement teams to ensure uninterrupted access to key therapies. Consequently, stakeholders must balance acute operational needs with medium- to long-term investments in pipeline development, stewardship programs, and alternative sourcing strategies. This introduction sets the stage for a structured examination of transformative shifts, tariff-related headwinds, segmentation intelligence, regional differences, competitive dynamics, recommended actions, and research rigor that underpins the report.

Analysis of the converging clinical, manufacturing, and distribution transformations that are redefining hospital infection therapeutics and stakeholder collaboration

The hospital infection therapeutics sector is undergoing transformative shifts driven by several concurrent trends that are reshaping clinical decision-making and supply chain structures. Advances in rapid diagnostics and point-of-care testing are enabling more targeted therapy selection, which is prompting a gradual pivot from broad empirical regimens to precision-targeted approaches. At the same time, stewardship programs are increasingly intertwined with procurement incentives, creating a feedback loop in which formulary decisions are informed by both clinical efficacy and resistance mitigation imperatives.

Parallel to clinical innovation, distribution models are evolving. Increased digitalization of procurement, growth in online pharmacy fulfillment, and pressure on wholesaler margins are motivating hospitals and health systems to reassess direct purchasing, consignment models, and strategic inventory buffers. Manufacturing trends are also significant; a shift toward specialized manufacturing for parenteral formulations and sterile injectables, combined with increasing scrutiny of quality and regulatory compliance, means supply continuity depends on robust supplier qualification and geographic diversification of critical inputs. These shifts collectively demand that clinical leaders work more closely with supply chain and commercial teams to harmonize therapeutic strategy with sourcing reliability and cost management.

Comprehensive analysis of how new tariff dynamics will compound supply chain fragility, procurement complexity, and clinical substitution strategies in hospital therapeutics

Tariff policy changes exert a powerful influence across hospital infection therapeutics even when they do not directly affect finished medicines. Increased duties on active pharmaceutical ingredients, sterile componentry, single-use devices, and packaging can raise landed costs and compress margins for manufacturers and distributors. As a consequence, procurement teams face heightened complexity in cost forecasting and contract negotiation, while manufacturers reassess supplier footprints and consider reshoring or nearshoring of critical production stages.

The tariff environment also exacerbates existing supply chain fragilities for parenteral and sterile products, where specialized equipment and validated production sites limit rapid capacity scaling. Hospitals that rely on just-in-time inventory models may experience greater exposure to intermittent shortages, prompting a strategic recalibration toward safety stock, multi-sourcing, and longer contract terms with clause structures that address force majeure and cost pass-through. In parallel, increased import costs can incentivize local manufacturing investment, but such transitions require capital, regulatory relocation, and time, meaning near-term impacts will mainly be managed through contracting strategies and inventory policies.

Clinically, tariff-related shifts can alter the availability and procurement prioritization of certain drug classes. Facilities may prioritize therapeutically equivalent generics or alternative antiseptic formulations to maintain continuity of care. Consequently, antimicrobial stewardship teams must work with procurement and formulary committees to update treatment pathways and ensure substitutions maintain clinical effectiveness while conforming to stewardship goals. Overall, tariff changes act as a forcing function that accelerates coordination across clinical, supply chain, regulatory, and finance functions.

Key Segmentation Insights Across Drug Class, Route of Administration, End User, Distribution Channel, and Application

Understanding the market requires a granular view by drug class, route of administration, end user, distribution channel, and application. The drug class landscape spans antibiotics, antifungals, antiseptics, and antivirals; within antibiotics there are subclasses including carbapenems, cephalosporins, fluoroquinolones, macrolides, and penicillins, while antifungals encompass azoles, echinocandins, and polyenes, antiseptics include alcohol-based preparations, chlorhexidine, and iodophors, and antivirals cover therapies for hepatitis B, hepatitis C, HIV, and influenza. Each of these categories presents distinct clinical usage patterns, stewardship considerations, manufacturing requirements, and regulatory pathways, which together influence procurement priorities and hospital formularies.

Routes of administration are a critical determinant of clinical deployment and supply complexities, with inhalation, oral, parenteral, and topical modalities shaping both clinical pathways and logistics; parenteral delivery in particular breaks down into intramuscular, intravenous, and subcutaneous forms that require specialized sterile manufacturing, cold chain considerations, and nursing competencies for administration. End users such as ambulatory surgery centers, clinics, home healthcare settings, and hospitals differ in purchasing power, storage infrastructure, and treatment protocols, necessitating tailored distribution approaches and patient education strategies. Distribution channels also vary between hospital pharmacy, online pharmacy, retail pharmacy, and wholesalers, each carrying distinct lead times, contractual norms, and compliance obligations.

Application segments-palliative, prophylaxis, and treatment-drive therapeutic selection and inventory planning. Prophylaxis itself subdivides into post-operative and pre-operative use cases that align with scheduling and surgical services, while treatment divides into empirical and targeted therapy, which requires different diagnostic and stewardship support. Integrating these segmentation layers enables stakeholders to better align clinical pathways with supply chain design, ensuring that the right formulation, route, and distribution channel are matched to the appropriate end user and application.

Key Regional Insights and How Geographic Dynamics Shape Clinical Adoption, Manufacturing, and Distribution Strategies

Regional dynamics exert a strong influence on therapeutic availability, regulatory expectations, and commercial strategies across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, consolidation among hospital systems and an emphasis on value-based procurement drive demand for therapies that demonstrate clear clinical and economic benefits, while distribution networks are often oriented toward centralized group purchasing and integrated supply agreements. By contrast, Europe, Middle East & Africa present heterogenous regulatory environments and procurement frameworks where national regulations, reimbursement mechanisms, and regional manufacturing hubs shape access and pricing. Policy initiatives stressing antimicrobial stewardship and infection prevention can also vary significantly across jurisdictions.

Asia-Pacific offers diverse dynamics with rapidly expanding healthcare capacity in some markets and advanced manufacturing capabilities in others. Several countries in the region prioritize local production and export-oriented pharmaceutical industries, affecting global supply chains for active pharmaceutical ingredients and sterile components. These geographic differences require manufacturers and distributors to adopt differentiated go-to-market approaches, invest in regulatory intelligence, and develop localized supply chain redundancies. Overall, regional strategy must account for regulatory timelines, procurement customs, manufacturing concentration, and clinical practice variation to ensure both availability and appropriate clinical use.

Key Companies Insights Highlighting Competitive Positioning, Innovation Focus, and Supply Chain Roles

The competitive landscape spans multinational pharmaceutical innovators, specialist biotech companies focused on novel antimicrobials and antivirals, generics manufacturers, and distributors that facilitate hospital access. Industry leaders with broad infectious disease portfolios often combine antiviral and antibacterial R&D with large-scale manufacturing and established distribution networks, enabling rapid deployment of new therapies when clinically validated. Specialist biotech firms and academic spinouts are frequently the source of next-generation agents and adjunctive therapies, while generics and contract manufacturers play a vital role in maintaining cost-effective access and production resilience.

Distribution and pharmacy service providers increasingly differentiate through value-added services such as clinical support tools, stewardship analytics, and managed inventory solutions. This trend has elevated the importance of partnerships between manufacturers and distributors to ensure that stewardship objectives and formulary decisions are supported by timely supply and clinician education. Additionally, companies investing in sterile manufacturing capacity and quality systems are better positioned to serve the hospital parenteral market, where regulatory scrutiny and the need for validated production present high barriers to entry. Insight into these corporate strategies helps stakeholders evaluate partner selection, potential acquisition targets, and collaboration opportunities to strengthen supply continuity and clinical outcomes.

Actionable Recommendations for Industry Leaders to Strengthen Resilience, Stewardship, and Commercial Performance

Industry leaders should prioritize cross-functional governance that brings together clinical, procurement, regulatory, and commercial teams to align on formulary decisions, contract structures, and contingency planning. Strengthening supplier qualification processes and diversifying sources for active pharmaceutical ingredients and sterile components reduces exposure to geographic and policy disruptions. At the same time, investing in diagnostic enablement and stewardship analytics helps shift utilization toward targeted therapy, preserving clinical efficacy and slowing resistance trends.

Commercial and distribution strategies must adapt to evolving procurement behaviors by offering flexible contracting models, accredited supply assurances, and educational support for clinical adoption. Manufacturers with capabilities in sterile manufacturing and robust quality systems should consider capacity signaling and strategic partnerships to support hospital needs. Additionally, building scenario planning into strategic reviews will help organizations respond to tariff changes, regulatory shifts, and sudden demand spikes by clearly defining trigger points for inventory adjustments, alternative sourcing, or therapeutic substitution. Collectively, these steps enhance preparedness while aligning commercial incentives with clinical quality objectives.

Research Methodology Explaining Data Sources, Analytical Frameworks, and Validation Approaches Underpinning Findings

The research approach combined primary engagement with clinical leaders, procurement professionals, and industry executives alongside secondary analysis of regulatory filings, quality guidance, and open-source industry reporting. Qualitative interviews provided context on operational constraints and adoption barriers, while supply chain mapping identified critical nodes for active pharmaceutical ingredient sourcing, sterile componentry, and distribution flows. The analytical framework integrated clinical pathway mapping with supplier risk assessment and commercial channel evaluation to generate holistic insights.

Validation was achieved through triangulation across interview feedback, manufacturer disclosures, and publicly available regulatory action summaries. Scenario analysis was applied to assess resilience under supply disruption and policy shifts, with particular attention to parenteral manufacturing constraints and distribution channel flexibility. Emphasis was placed on transparent assumptions and the reproducibility of method steps so that stakeholders can adapt the approach to their internal decision-making and perform targeted due diligence where necessary.

Conclusion Summarizing Strategic Imperatives for Clinical Outcomes, Supply Continuity, and Collaborative Execution

Hospital infection therapeutics sit at the intersection of clinical urgency and operational complexity. Ensuring patient safety and effective therapeutic access requires integrated action across clinical stewardship, procurement policy, manufacturing strategy, and distribution design. Recent changes in trade policy, evolving clinical diagnostics, and shifting distribution models compound the need for cross-functional coordination and contingency planning. Organizations that proactively diversify supply, invest in diagnostic-driven prescribing, and structure flexible commercial agreements will be better positioned to maintain continuity and support optimal clinical outcomes.

Ultimately, success depends on translating insight into operational practice: aligning formularies with stewardship objectives, qualifying multiple supply sources for critical sterile products, and leveraging partnerships that provide both clinical outreach and inventory solutions. By taking a strategic, integrated approach, hospitals, manufacturers, and distributors can mitigate near-term disruptions and build the adaptive capabilities necessary to respond to future challenges in infection therapeutics.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Growth of hospital-based antimicrobial stewardship programs reducing resistance emergence by optimizing antibiotic usage
  • 5.2. Adoption of rapid molecular diagnostics enabling targeted infection therapy within hours of patient admission
  • 5.3. Increasing integration of AI-driven predictive analytics for early detection of hospital-acquired infections
  • 5.4. Development of bacteriophage cocktails targeting multidrug-resistant Pseudomonas aeruginosa in critical care settings
  • 5.5. Emergence of monoclonal antibody adjunctive therapies for prevention of Clostridioides difficile infection recurrence
  • 5.6. Implementation of antimicrobial surface coatings on medical devices to prevent biofilm formation in catheters
  • 5.7. Expansion of telehealth-based infectious disease consultation services to manage inpatient antimicrobial protocols
  • 5.8. Regulatory initiatives mandating real-time antibiotic usage tracking and reporting across hospital networks
  • 5.9. Advances in CRISPR-Cas antimicrobials designed to selectively eliminate drug-resistant bacterial strains in hospitals
  • 5.10. Utilization of next-generation sequencing for real-time surveillance of resistance gene transmission pathways

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Hospital Infection Therapeutics Market, by Drug Class

  • 8.1. Antibiotics
    • 8.1.1. Carbapenems
    • 8.1.2. Cephalosporins
    • 8.1.3. Fluoroquinolones
    • 8.1.4. Macrolides
    • 8.1.5. Penicillins
  • 8.2. Antifungals
    • 8.2.1. Azoles
    • 8.2.2. Echinocandins
    • 8.2.3. Polyenes
  • 8.3. Antiseptics
    • 8.3.1. Alcohol Based
    • 8.3.2. Chlorhexidine
    • 8.3.3. Iodophors
  • 8.4. Antivirals
    • 8.4.1. Anti-HBV
    • 8.4.2. Anti-HCV
    • 8.4.3. Anti-HIV
    • 8.4.4. Anti-Influenza

9. Hospital Infection Therapeutics Market, by Route Of Administration

  • 9.1. Inhalation
  • 9.2. Oral
  • 9.3. Parenteral
    • 9.3.1. Intramuscular
    • 9.3.2. Intravenous
    • 9.3.3. Subcutaneous
  • 9.4. Topical

10. Hospital Infection Therapeutics Market, by End User

  • 10.1. Ambulatory Surgery Centers
  • 10.2. Clinics
  • 10.3. Home Healthcare
  • 10.4. Hospitals

11. Hospital Infection Therapeutics Market, by Distribution Channel

  • 11.1. Hospital Pharmacy
  • 11.2. Online Pharmacy
  • 11.3. Retail Pharmacy
  • 11.4. Wholesalers

12. Hospital Infection Therapeutics Market, by Application

  • 12.1. Palliative
  • 12.2. Prophylaxis
    • 12.2.1. Post-Operative
    • 12.2.2. Pre-Operative
  • 12.3. Treatment
    • 12.3.1. Empirical
    • 12.3.2. Targeted Therapy

13. Hospital Infection Therapeutics Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Hospital Infection Therapeutics Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Hospital Infection Therapeutics Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Pfizer Inc.
    • 16.3.2. Merck & Co., Inc.
    • 16.3.3. GlaxoSmithKline plc
    • 16.3.4. Sanofi S.A.
    • 16.3.5. F. Hoffmann-La Roche Ltd
    • 16.3.6. Novartis AG
    • 16.3.7. Bayer AG
    • 16.3.8. AbbVie Inc.
    • 16.3.9. Astellas Pharma Inc.
    • 16.3.10. DAIICHI SANKYO COMPANY

LIST OF FIGURES

  • FIGURE 1. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. HOSPITAL INFECTION THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. HOSPITAL INFECTION THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. HOSPITAL INFECTION THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY CARBAPENEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY CARBAPENEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY CARBAPENEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY CARBAPENEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY CARBAPENEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY CARBAPENEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY CEPHALOSPORINS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY CEPHALOSPORINS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY CEPHALOSPORINS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY CEPHALOSPORINS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY CEPHALOSPORINS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY CEPHALOSPORINS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY FLUOROQUINOLONES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY FLUOROQUINOLONES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY FLUOROQUINOLONES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY FLUOROQUINOLONES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY FLUOROQUINOLONES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY FLUOROQUINOLONES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY MACROLIDES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY MACROLIDES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY MACROLIDES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY MACROLIDES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY MACROLIDES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY MACROLIDES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY PENICILLINS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY PENICILLINS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY PENICILLINS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY PENICILLINS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY PENICILLINS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY PENICILLINS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY AZOLES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY AZOLES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY AZOLES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY AZOLES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY AZOLES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY AZOLES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ECHINOCANDINS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ECHINOCANDINS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ECHINOCANDINS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ECHINOCANDINS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ECHINOCANDINS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ECHINOCANDINS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY POLYENES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY POLYENES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY POLYENES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY POLYENES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY POLYENES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY POLYENES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTISEPTICS, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTISEPTICS, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTISEPTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTISEPTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTISEPTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTISEPTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTISEPTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTISEPTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ALCOHOL BASED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ALCOHOL BASED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ALCOHOL BASED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ALCOHOL BASED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ALCOHOL BASED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ALCOHOL BASED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY CHLORHEXIDINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY CHLORHEXIDINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY CHLORHEXIDINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY CHLORHEXIDINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY CHLORHEXIDINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY CHLORHEXIDINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY IODOPHORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY IODOPHORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY IODOPHORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY IODOPHORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY IODOPHORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY IODOPHORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTI-HBV, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTI-HBV, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTI-HBV, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTI-HBV, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTI-HBV, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTI-HBV, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTI-HCV, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTI-HCV, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTI-HCV, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTI-HCV, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTI-HCV, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTI-HCV, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTI-HIV, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTI-HIV, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTI-HIV, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTI-HIV, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTI-HIV, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTI-HIV, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTI-INFLUENZA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTI-INFLUENZA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTI-INFLUENZA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTI-INFLUENZA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTI-INFLUENZA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTI-INFLUENZA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INHALATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INHALATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INHALATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INHALATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INHALATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INHALATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY PARENTERAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY PARENTERAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY PARENTERAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY PARENTERAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY PARENTERAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY TOPICAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY TOPICAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY HOME HEALTHCARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY HOME HEALTHCARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY HOME HEALTHCARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY HOME HEALTHCARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY WHOLESALERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY WHOLESALERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY WHOLESALERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY WHOLESALERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY WHOLESALERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY WHOLESALERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY PALLIATIVE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY PALLIATIVE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY PALLIATIVE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY PALLIATIVE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY PALLIATIVE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY PALLIATIVE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY PROPHYLAXIS, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY PROPHYLAXIS, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY PROPHYLAXIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY PROPHYLAXIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY PROPHYLAXIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY PROPHYLAXIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY PROPHYLAXIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY PROPHYLAXIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY POST-OPERATIVE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY POST-OPERATIVE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY POST-OPERATIVE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY POST-OPERATIVE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY POST-OPERATIVE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY POST-OPERATIVE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY PRE-OPERATIVE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY PRE-OPERATIVE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY PRE-OPERATIVE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY PRE-OPERATIVE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY PRE-OPERATIVE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY PRE-OPERATIVE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY TREATMENT, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY TREATMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY TREATMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY TREATMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY TREATMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY TREATMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY TREATMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY EMPIRICAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY EMPIRICAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY EMPIRICAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY EMPIRICAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY EMPIRICAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY EMPIRICAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 269. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 270. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 271. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 272. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 273. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 274. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 275. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 276. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 277. AMERICAS HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 278. AMERICAS HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 279. AMERICAS HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 280. AMERICAS HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 281. AMERICAS HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
  • TABLE 282. AMERICAS HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2025-2032 (USD MILLION)
  • TABLE 283. AMERICAS HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, 2018-2024 (USD MILLION)
  • TABLE 284. AMERICAS HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTIFUNGALS, 2025-2032 (USD MILLION)
  • TABLE 285. AMERICAS HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTISEPTICS, 2018-2024 (USD MILLION)
  • TABLE 286. AMERICAS HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTISEPTICS, 2025-2032 (USD MILLION)
  • TABLE 287. AMERICAS HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2024 (USD MILLION)
  • TABLE 288. AMERICAS HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2025-2032 (USD MILLION)
  • TABLE 289. AMERICAS HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 290. AMERICAS HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 291. AMERICAS HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2018-2024 (USD MILLION)
  • TABLE 292. AMERICAS HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY PARENTERAL, 2025-2032 (USD MILLION)
  • TABLE 293. AMERICAS HOSPITAL